| Co-Investigator(Kenkyū-buntansha) |
丸 祐一 鳥取大学, 地域学部, 准教授 (10466708)
高島 響子 国立研究開発法人国立国際医療研究センター, その他部局等, 上級研究員 (10735749)
井上 悠輔 東京大学, 医科学研究所, 准教授 (30378658)
東島 仁 山口大学, 国際総合科学部, 准教授 (80579326)
中田 はる佳 国立研究開発法人国立がん研究センター, 社会と健康研究センター, 研究員 (10592248)
|
|---|
| Budget Amount *help |
¥119,210,000 (Direct Cost: ¥91,700,000、Indirect Cost: ¥27,510,000)
Fiscal Year 2019: ¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2018: ¥23,270,000 (Direct Cost: ¥17,900,000、Indirect Cost: ¥5,370,000)
Fiscal Year 2017: ¥23,270,000 (Direct Cost: ¥17,900,000、Indirect Cost: ¥5,370,000)
Fiscal Year 2016: ¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2015: ¥26,390,000 (Direct Cost: ¥20,300,000、Indirect Cost: ¥6,090,000)
|
|---|
| Outline of Final Research Achievements |
Our ELSI project research was conducted to redefine the roles and responsibilities of researchers in cancer genomic medicine and to solve new ethical dilemmas brought by emerging technologies. We identified topics such as patient and public involvement (PPI), data and benefit sharing, ethics of small-scare studies, compassionate use and right to try, disclosure of secondary findings from clinical sequencing and right not to know, genetic discrimination and stigmatization and health care powered by AI/cognitive computing. We conducted empirical research as well as theoretical research in collaboration with patient groups. We published 31 papers, including 6 English peer-reviewed papers.
|
